DexcomDXCMEarnings & Financial Report
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Revenue
$1.0B
Gross Profit
$626.7M
Operating Profit
$158.0M
Net Profit
$143.5M
Gross Margin
62.4%
Operating Margin
15.7%
Net Margin
14.3%
YoY Growth
15.3%
EPS
$0.35
Dexcom Q2 FY2024 Financial Summary
Dexcom reported revenue of $1.0B (up 15.3% YoY) for Q2 FY2024, with a net profit of $143.5M (up 23.8% YoY) (14.3% margin). Cost of goods sold was $377.6M, operating expenses totaled $468.7M.
Key Financial Metrics
| Total Revenue | $1.0B |
|---|---|
| Net Profit | $143.5M |
| Gross Margin | 62.4% |
| Operating Margin | 15.7% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Dexcom Q2 FY2024 revenue of $1.0B breaks down across 2 segments, led by Sales Channel Through Intermediary at $860.1M (85.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Sales Channel Through Intermediary | $860.1M | 85.6% |
| Sales Channel Directly To Consumer | $144.2M | 14.4% |
Dexcom Revenue by Segment — Quarterly Trend
Dexcom revenue by segment across the last 4 reported quarters, showing how each business line (such as Sales Channel Through Intermediary and Sales Channel Directly To Consumer) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Sales Channel Through Intermediary | — | — | $1.0B | $977.8M |
| Sales Channel Directly To Consumer | — | — | $183.3M | $179.3M |
Dexcom Annual Revenue by Year
Dexcom annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.7B |
| 2024 | $4.0B |
Dexcom Quarterly Revenue & Net Profit History
Dexcom results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.3B | +21.6% | $267.3M | 21.2% |
| Q4 FY2025 | $1.3B | +13.1% | $267.3M | 21.2% |
| Q3 FY2025 | $1.2B | +21.6% | $283.8M | 23.5% |
| Q2 FY2025 | $1.2B | +15.2% | $179.8M | 15.5% |
| Q1 FY2025 | $1.0B | +12.5% | $105.4M | 10.2% |
| Q4 FY2024 | $1.1B | +7.6% | $151.7M | 13.6% |
| Q3 FY2024 | $994.2M | +2.0% | $134.6M | 13.5% |
| Q2 FY2024 | $1.0B | +15.3% | $143.5M | 14.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $994.2M | $1.11B | $1.04B | $1.16B | $1.21B | $1.26B | $1.26B |
| YoY Growth | 15.3% | 2.0% | 7.6% | 12.5% | 15.2% | 21.6% | 13.1% | 21.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.80B | $6.35B | $6.48B | $6.75B | $7.33B | $7.50B | $6.34B | $6.34B |
| Liabilities | $4.36B | $4.37B | $4.38B | $4.49B | $4.75B | $4.77B | $3.59B | $3.59B |
| Equity | $2.43B | $1.98B | $2.10B | $2.27B | $2.57B | $2.73B | $2.75B | $2.75B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $279.4M | $199.5M | $301.4M | $183.8M | $303.0M | $659.9M | $294.0M |